新西兰增加了黑瘤治疗机会,为高级疗法提供了6.04亿美元的资金。 New Zealand boosts melanoma treatment access, funding $604 million for advanced therapies.

新西兰药房已宣布增加资金和增加获得先进的黑素瘤治疗的机会,包括免疫疗法和诸如Keyturda、Tafinlar和Mekenist等定向疗法。 New Zealand's Pharmac has announced increased funding and access to advanced melanoma treatments, including immunotherapies and targeted therapies like Keytruda, Tafinlar, and Mekenist. 此举使约285名3B至4黑瘤患者受益,使新西兰更接近国际护理标准。 This move benefits around 285 patients with stage 3B to 4 melanoma, bringing New Zealand closer to international care standards. 这6.04亿美元的资金提升也扩大了获得其他癌症治疗的机会,目的是改善该国癌症护理的总体情况。 The $604 million funding uplift also expands access to other cancer treatments, aiming to improve overall cancer care in the country.